The neutralizing WISP-1 antibody treatment led to the attenuation of lung fibrosis and increased the survival rate in the bleomycin–mouse model, along with reduced collagen deposition and expression of genes associated with EMT (epithelial–mesenchymal transition) [63]. The gene discussed is CCN4; the disease is pulmonary fibrosis.